down arrow

Estrella Immunopharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2975841048
USD
1.58
0.02 (1.28%)

Dec 18

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.411.64

52 Week

0.733.15
Valuation
Technical
Day's Volume

CASH

272.31 k

Shareholding (Jun 2025)

FII

0.03%

Held by 2 FIIs

DII

98.85%

Held by 1 DIIs

Promoter

0.00%

How big is Estrella Immunopharma, Inc.?

22-Jun-2025

As of March 2023, Estrella Immunopharma, Inc. has an unavailable market capitalization and no valid data for net sales or net profit for the latest four quarters. Shareholder's funds are 22.61 million, and total assets amount to 43.08 million.

Market Cap: As of March 2023, Estrella Immunopharma, Inc. has a market capitalization value that is not available. Therefore, it cannot be classified into any market cap type.<BR><BR>Recent Quarterly Performance: As of March 2023, there is no valid data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: As of March 2023, the Shareholder's Funds are 22.61 million, and the Total Assets amount to 43.08 million.

Read More

What does Estrella Immunopharma, Inc. do?

22-Jun-2025

Estrella Immunopharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with no dividend yield and significant negative financial metrics.

Overview: <BR>Estrella Immunopharma, Inc. operates within the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Market cap: Micro Cap<BR><BR>Key Metrics: <BR>Industry: Pharmaceuticals & Biotechnology <BR>Dividend Yield: 0.00% <BR>Debt Equity: -999,999.00 <BR>Return on Equity: -999,999.00% <BR>Price to Book: 0.00 <BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is Estrella Immunopharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Estrella Immunopharma, Inc. shows a neutral trend with mixed indicators, as the stock has outperformed the S&P 500 recently but is down year-to-date, suggesting a cautious approach is advisable.

As of 12 September 2025, the technical trend for Estrella Immunopharma, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed indicators influencing this position. The weekly MACD is bullish, while the RSI is bearish, indicating conflicting momentum signals. The Bollinger Bands are bullish on both weekly and monthly time frames, suggesting potential upward volatility. However, daily moving averages remain mildly bearish, which tempers the overall outlook. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, returning 7.69% and 21.81% respectively, compared to the S&P's 1.05% and 2.33%. However, year-to-date, the stock is down 6.67%, while the S&P 500 has gained 12.22%. Overall, the mixed signals suggest a cautious approach is warranted.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 37 Million ()

stock-summary
P/E

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.22

stock-summary
Return on Equity

-999,999.00%

stock-summary
Price to Book

-6.08

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
41.07%
0%
41.07%
6 Months
69.64%
0%
69.64%
1 Year
39.82%
0%
39.82%
2 Years
30.58%
0%
30.58%
3 Years
-84.57%
0%
-84.57%
4 Years
-84.01%
0%
-84.01%
5 Years
0%
0%
0.0%

Estrella Immunopharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
0.00%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
3.13%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
EV to EBIT
EV to EBITDA
EV to Capital Employed
EV to Sales
PEG Ratio
NA
Dividend Yield
ROCE (Latest)
ROE (Latest)
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (1.12%)

Foreign Institutions

Held by 2 Foreign Institutions (0.03%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -37.50% vs -3,900.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.50",
          "val2": "-3.90",
          "chgp": "-41.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.50",
          "val2": "-4.00",
          "chgp": "-37.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -790.00% vs -400.00% in Dec 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.90",
          "val2": "-1.60",
          "chgp": "-456.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.90",
          "val2": "-1.00",
          "chgp": "-790.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-5.50
-3.90
-41.03%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.50
-4.00
-37.50%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -37.50% vs -3,900.00% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-8.90
-1.60
-456.25%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-8.90
-1.00
-790.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -790.00% vs -400.00% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About Estrella Immunopharma, Inc. stock-summary
stock-summary
Estrella Immunopharma, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."